文献速递胸部肿瘤放疗

初次肺SBRT后孤立局部复发再程SBRT挽救的安全性与疗效

Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT.
PubMed 文献 · Radiother Oncol · 2019-08-31

本研究基于前瞻性登记数据,纳入2008至2017年21例早期NSCLC初次SBRT后孤立局部复发并接受再程SBRT的患者,两程均为3-5次、BED10≥100 Gy。再程SBRT后中位总生存39个月,2年原发肿瘤控制81%、区域淋巴结控制89%、远地控制75%、总生存68%,仅见2级肺炎和2级胸壁毒性,无3级及以上毒性。

要点

  • 再程SBRT后2年原发肿瘤控制81%、总生存68%。
  • 仅2例2级肺炎、4例2级胸壁毒性,无3级及以上毒性。
  • 再程SBRT后中位总生存为39个月。

核心结论

  • 初次肺SBRT后孤立局部失败行再程SBRT看似安全,治疗相关毒性低且肿瘤控制率令人鼓舞。

研究设计与样本

  • 利用前瞻性登记数据库识别2008至2017年接受再程SBRT的早期NSCLC孤立局部复发患者,共21例。
  • 两程SBRT均为3-5次、BED10≥100 Gy,局部失败定义为距初始PTV 1 cm内或两次治疗≥25%等剂量线重叠。
  • 采用Kaplan-Meier法估计生存。

主要发现

  • 初次SBRT至再程SBRT的中位间隔为23个月(范围7-52个月),6例(29%)为中心型肿瘤。
  • 再程SBRT后中位随访24个月(范围3-60个月),中位总生存39个月。
  • 再程SBRT后2年原发肿瘤控制81%、区域淋巴结控制89%、远地控制75%、总生存68%。
  • 2级肺炎2例(10%),2级胸壁毒性4例(19%),未见3级及以上毒性。

关键数值与推荐

  • 局部失败定义为距初始PTV 1 cm内或两次治疗≥25%等剂量线重叠。
  • 距PTV超过1 cm且无≥25%重叠,或伴其他复发部位者被排除。
  • 两程SBRT均为3-5次、BED10≥100 Gy。

临床怎么用

  • 对初次肺SBRT后孤立局部复发且符合上述局部失败定义的患者,可考虑再程SBRT作为挽救治疗。
  • 再程SBRT需关注2级肺炎和胸壁毒性风险。

局限性

  • 样本量小(21例),来自单前瞻性登记数据库。
  • 中位随访24个月,随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Optimal management of isolated local recurrences after stereotactic body radiation therapy (SBRT) for early non-small cell lung cancer (NSCLC) is unknown and literature describing repeat SBRT for in-field recurrences after initial SBRT are sparse. We investigate the safety and efficacy of salvage SBRT for isolated local failures after initial SBRT for NSCLC. METHODS/MATERIALS: Patients receiving SBRT for isolated local recurrence after initial SBRT for early NSCLC were identified using a prospective registry. Both courses were 3-5 fractions with a biologically effective dose (BED10) of ≥100 Gy. Local failure was defined as within 1 cm of the initial planning target volume (PTV) or an overlap of the ≥25% isodose lines of the first and second treatments. Failures >1 cm beyond the PTV and without ≥25% overlap, or with additional recurrence sites were excluded. Kaplan-Meier analysis was used to estimate survival. RESULTS: A total 21 patients receiving salvage SBRT from 2008 to 2017 were identified. Median interval from initial SBRT to salvage SBRT was 23 months (7-52). Six patients (29%) had central tumors. Median follow-up time from salvage SBRT was 24 months (3-60). Median overall survival after salvage was 39 months. After reirradiation, two-year primary tumor control was 81%, regional nodal control was 89%, distant control was 75% and overall survival was 68%. Grade 2 pneumonitis occurred in 2 patients (10%) and grade 2 chest wall toxicity in 4 patients (19%). No grade 3+ toxicity was observed. CONCLUSIONS: Salvage SBRT for isolated local failures after initial SBRT appears safe, with low treatment-related toxicity and encouraging rates of tumor control.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kennedy WR, Gabani P, Nikitas J, et al. Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT. Radiother Oncol. 2019. PMID: 31481272. doi:10.1016/j.radonc.2019.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。